biostudies-literatureUnknown1(4)Wood RA<h4>Background</h4>Food allergy is common and causes substantial morbidity and even mortality. Safe and effective treatments for food allergy would therefore be highly desirable, especially for individuals with multiple food allergies.<h4>Objectives</h4>Our aim was to describe a phase 3 study on treatment of patients with multiple food allergies with omalizumab.<h4>Methods</h4>The study was developed as a collaboration between the Consortium for Food Allergy Research, the National Institute of Allergy and Infectious Diseases, and 2 industry sponsors (Genentech and Novartis).<h4>Results</h4>The study is currently under way, enrolling participants from age 1 year to age 55 years who are allergic to peanut and at least 2 other foods (including milk, egg, wheat, cashew, hazelnut, and walnut). The journal of allergy and clinical immunology. Global225-232https://www.ebi.ac.uk/biostudies/studies/S-EPMC10509974biostudies-literatureProtocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).PMC10509974Kim EHOUtMATCH study teamFogel RBKulis MKaufman DBabineau DCMacPhee MWood RAUddin ALigueros-Saylan MVickery BPChinthrajah RSHamrah SSpergel JMJones SMPoyser JBird JADavidson WRudman Spergel AKShreffler WGIqbal AUmetsu DTVeri MSicherer SHMudd KLussier SLeung DYMLong ATogias AfalseProtocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).<h4>Background</h4>Food allergy is common and causes substantial morbidity and even mortality. Safe and effective treatments for food allergy would therefore be highly desirable, especially for individuals with multiple food allergies.<h4>Objectives</h4>Our aim was to describe a phase 3 study on treatment of patients with multiple food allergies with omalizumab.<h4>Methods</h4>The study was developed as a collaboration between the Consortium for Food Allergy Research, the National Institute of Allergy and Infectious Diseases, and 2 industry sponsors (Genentech and Novartis).<h4>Results</h4>The study is currently under way, enrolling participants from age 1 year to age 55 years who are allergic to peanut and at least 2 other foods (including milk, egg, wheat, cashew, hazelnut, and walnut). 2022-01-01T00:00:00Z2022 Nov2025-04-05T15:24:43.242Z2025-04-05T15:24:43.242ZS-EPMC105099743777953410.1016/j.jacig.2022.05.006